3 research outputs found
an individual participant data meta-analysis
Background The impact of neuraminidase inhibitors (NAIs) on influenza-related
pneumonia (IRP) is not established. Our objective was to investigate the
association between NAI treatment and IRP incidence and outcomes in patients
hospitalised with A(H1N1)pdm09 virus infection. Methods A worldwide meta-
analysis of individual participant data from 20 634 hospitalised patients with
laboratory-confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n =
613) ‘pandemic influenza’. The primary outcome was radiologically confirmed
IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling,
adjusting for NAI treatment propensity, antibiotics and corticosteroids.
Results Of 20 634 included participants, 5978 (29·0%) had IRP; conversely,
3349 (16·2%) had confirmed the absence of radiographic pneumonia (the
comparator). Early NAI treatment (within 2 days of symptom onset) versus no
NAI was not significantly associated with IRP [adj. OR 0·83 (95% CI 0·64–1·06;
P = 0·136)]. Among the 5978 patients with IRP, early NAI treatment versus none
did not impact on mortality [adj. OR = 0·72 (0·44–1·17; P = 0·180)] or
likelihood of requiring ventilatory support [adj. OR = 1·17 (0·71–1·92; P =
0·537)], but early treatment versus later significantly reduced mortality
[adj. OR = 0·70 (0·55–0·88; P = 0·003)] and likelihood of requiring
ventilatory support [adj. OR = 0·68 (0·54–0·85; P = 0·001)]. Conclusions Early
NAI treatment of patients hospitalised with A(H1N1)pdm09 virus infection
versus no treatment did not reduce the likelihood of IRP. However, in patients
who developed IRP, early NAI treatment versus later reduced the likelihood of
mortality and needing ventilatory support
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo